CNBC Pro

Mizuho downgrades Pfizer to neutral, says stock has limited upside from here

Pharmaceutical Pfizer Inc. said that an oral drug for treating COVID-19 could be available by end of 2021.
Soumyabrata Roy | NurPhoto | Getty Images

Investors should trim their bets on Pfizer until the pharmaceutical giant shows what's next for the company after the success of its Covid-19 vaccine, investment firm Mizuho said in a note to clients.

Pfizer beat earnings expectations on the top and bottom lines on Tuesday in a first-quarter report that Mizuho analyst Vamil Divan called "stunning." However, Divan downgraded the stock to neutral from buy on Thursday, saying in a note to clients that it wasn't clear what the next upside driver would be.

More In Street Calls

Here are Friday's biggest analyst calls: Tesla, Nike, Generac, Microsoft, Disney, Micron & more
CNBC ProHere are Friday's biggest analyst calls: Tesla, Nike, Generac, Microsoft, Disney, Micron & more
Buy this electric vehicle charging company poised to rally 120% as adoption grows, Credit Suisse says
CNBC ProBuy this electric vehicle charging company poised to rally 120% as adoption grows, Credit Suisse says
It's time to buy this residential generator leader trading at attractive levels, Cowen says
CNBC ProIt's time to buy this residential generator leader trading at attractive levels, Cowen says